As the world's first ARB/CCB compound preparation, Bebot combines two antihypertensive drugs which are widely used in clinic in the world-valsartan (angiotensin receptor antagonist, ARB) and amlodipine (calcium channel blocker, CCB). It has been listed in more than 50 countries around the world, and it was approved by China State Food and Drug Administration on September 29th, 2009. It can be widely used in all kinds of hypertension patients. Research shows that Bebot can effectively control the blood pressure of nearly 90% patients, which is suitable for the characteristics of China population. 20 10 On September 25th, the research on "China Status II" was officially launched. According to the plan, the number of patients participating in the study will reach 40,000, which will become the largest prospective clinical study of hypertension drugs at home and abroad. So Bebot has no suspense.
I hope I can help you.